Evidence map›Paper›PMID 34867025›Full record

ArticleSaudi journal of biological sciences2021

Diacerein ameliorates kidney injury induced by cisplatin in rats by activation of Nrf2/Ho-1 pathway and Bax down-regulation.

Nashwa Barakat, Lamiaa A A Barakat, Mahmoud M Zakaria, Salma M Khirallah

Open access · hybridAbstract read
In one paragraph

Article in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Potential Medicinal Value of Rhein for Diabetic Kidney Disease.Chinese journal of integrative medicine · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nashwa BarakatUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Lamiaa A A BarakatDepartment of Biochemistry, Faculty of Science, Port Said University, Port Said, Egypt.
Mahmoud M ZakariaUrology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Salma M KhirallahDepartment of Biochemistry, Faculty of Science, Port Said University, Port Said, Egypt.
Mansoura University · EGPort Said University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is an antineoplastic medicine used for solid tumor treatment. The main side effect that limits its dose is nephrotoxicity. Diacerein has been used for the treatment of joint diseases like osteoarthritis. It also has exhibited analgesic effects and antipyretic activities in animal models so this study targets to indicate the diacerein effect on nephrotoxicity induced by cisplatin in rats. Rats were distributed into four groups: normal healthy control; diacerein, which received diacerein daily by gastric gavage (50 mg/kg/day); cisplatin, which received only one intraperitoneal injection of cisplatin (6 mg/kg) and cisplatin and diacerein, which received diacerein daily after the cisplatin injection till 7th and 12th days, respectively. Diacerein treatment decreased kidney function markers so the cisplatin effect was reversed. Also, diacerein increased the renal antioxidants and decreased oxidative stress. Diacerein up-regulated Ho-1 (heme oxygenase 1), Nrf2 (Nuclear factor erythroid 2-related factor 2) and endothelial nitric oxide synthase (eNOS) genes expression, while down-regulated Bcl-2-associated X protein (Bax) gene expression. Furthermore, the renal transforming growth factor beta-1 (TGF-β1) decreased by the diacerein effect. Consequently, diacerein has a curative effect against cisplatin due to its anti-inflammatory, antioxidant, and antiapoptotic properties.

Indexed as

Bax, Bcl-2-associated X proteinCAT, catalaseCisplatinDiacereineNOS, endothelial nitric oxide synthaseHo-1, heme oxygenase 1MDA, malondialdehydeNephrotoxicityNrf2/Ho-1 pathwayNrf2, Nuclear factor erythroid 2–related factor 2SOD, superoxide dismutaseTGF-β1, transforming growth factor beta-1

Identifiers

PMID34867025
PMCPMC8626266
OpenAlexW3196053925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.